National Liver Cancer Screening Trial
This study is comparing two ways to screen for liver cancer (Hepatocellular Carcinoma or HCC) in people with liver cirrhosis or chronic hepatitis B. You would either receive standard care, which is a liver ultrasound with or without an AFP (alpha-fetoprotein) blood test, or a new screening method called GALAD. GALAD is a blood test that looks at three specific markers (AFP, AFP-L3%, and DCP) along with your age and sex. The goal is to see which screening method is better at finding liver cancer earlier, before it reaches a late stage. The study plans to enroll 5500 participants and will follow them for 5.5 years to see the results.
- Study design
- This is an interventional, randomized study comparing two screening methods. It plans to enroll 5500 participants.
- What's involved
- You would receive semi-annual (twice a year) screening, either with ultrasound and AFP or with the GALAD blood test. The study will last for 5.5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 5.5 years to assess the proportion of HCC detected at a late stage.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
National Liver Cancer Screening Trial
At a glance
Conditions
Where it's being run
19 sites across 12 statesStudy leadership
- Amit Singal, MD, MS · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of HCC detected at late stage5.5 years
Proportion of HCC detected at a late stage, defined as HCC beyond Milan Criteria (one tumor less than or equal to 5 cm or 2-3 tumors each less than or equal to 3 cm, in the absence of vascular invasion or extra-hepatic metastases)